Kevin Davies on Muck Rack

Kevin Davies

Verified
Washington, D.C.
As seen in: Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., The Waterstones Podcast, Medium, The Athletic, The New York Times, Nature, Post Outlook, The Daily Mirror, The Telegraph, TIME, PBS and
Author "EDITING HUMANITY: The CRISPR Revolution and the New Era of Genome Editing"; Exec Ed @CRISPRJournal, @GENbiotechjrnl; @hwaspeakers

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Kevin Davies’s Biography

Read Full Bio →

Author, editor, publisher and writer with >25 years experience . Founding editor of Nature Genetics and Bio-IT World; currently Executive Editor of The CRISPR Journal and Editor-at-Lare with GEN

Articles

Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell Assets

|
By Kevin Davies Verified, Alex Philippidis Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Genome Editing Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell... Researchers at work in Sangamo Therapeutics' laboratory. The pioneer gene editing biotech company has filed for Chapter 11 bankruptcy protection, and has agreed to sell some of its programs and platforms to Eli Lilly and Astellas, in deals subject to placing the winning bids at a future bankruptcy court auction.
Open in Who Shared View Duplicates (2) Issue with article?

Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review

|
By Alex Philippidis Verified, Kevin Davies Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Translational Medicine Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review Credit: EzumeImages / iStock / Getty Images Plus Fulcrum Therapeutics said today it is scrapping its lead pipeline program to develop pociredir as a treatment for sickle cell disease (SCD) and launching a “comprehensive” review of strategic alternatives, after the FDA told the company it had heightened concerns about the drug’s risks and benefits in fighting the disease.
Open in Who Shared Issue with article?

Smile Please: Wisconsin Welcomes FUJIFILM Cellular Dynamics New Headquarters

|
By Kevin Davies Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Bioprocessing Smile Please: Wisconsin Welcomes FUJIFILM Cellular Dynamics New Headquarters Wisconsin Governor Tony Evers (center) leads the ribbon-cutting ceremony at FUJIFILM Cellular Dynamics’ new headquarters and manufacturing facility in Madison, WI.
Open in Who Shared View Duplicates (3) Issue with article?
See all 224 licensed articles (230 Total)

Awards

Guggenheim Fellowship

2017 - Science writing
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified